Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
INBXthis companyInhibrx Biosciences Inc.	$90.97	-8.74×	153.07×	941.13×	-9.62×	-99.0%	-91.0%	-10386.5%	-10773.5%	-1752.2%	-117.4%	-10.6%	13.39×	0.14×	-11.07×	3.93×	0.0%	3	-1.53	2	C
ABSIAbsci Corporation	$11.05	-4.15×	2.52×	170.48×	-4.48×	-99.6%	-319.4%	-4454.2%	-4113.7%	-60.8%	-63.6%	-19.7%	0.03×	0.14×	-596.74×	6.57×	0.0%	4	39.57	1	C-
CLDXCelldex Therapeutics, Inc.	$31.21	-6.96×	3.43×	1,204.09×	-6.97×	-99.2%	100.0%	-19160.0%	-17253.3%	-49.1%	-53.9%	-11.8%	0×	0.1×	0×	10.49×	0.0%	2	16.42	2	C
GENBGenerate Biomedicines, Inc.	$13.88	-2.54×	-1.03×	19.87×	-2.78×	-546.2%	100.0%	-737.0%	-637.0%	33.0%	-89.4%	-32.2%	-0.11×	0.25×	-206.92×	2.85×	0.0%	—	—	1	C-
JANXJanux Therapeutics, Inc.	$13.70	-7.54×	0.89×	85.51×	-7.39×	-118.0%	79.7%	-1576.7%	-1136.3%	-11.9%	-16.0%	-9.7%	0.02×	0.27×	0×	39.04×	0.0%	3	8.27	2	C+
TECXTectonic Therapeutic, Inc.	$22.14	-5.15×	1.52×	0×	-1.81×	-27.7%	0.0%	0.0%	0.0%	-29.5%	-33.3%	-15.8%	0.01×	3.53×	-1,333.9×	26.63×	0.0%	1	15.21	2	C+
Peer median	—	-5.15×	1.52×	85.51×	-4.48×	-99.6%	79.7%	-1576.7%	-1136.3%	-29.5%	-53.9%	-15.8%	0.01×	0.25×	-206.92×	10.49×	0.0%	3	15.82	2	—